Full history for every metric is available with a Kvantra account
Surface Oncology, Inc. (SURF)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 13 | 59 | 15 | 126 | 3 | 30 | 30 |
| Operating profit | $m | -62 | -89 | |||||
| Net profit | $m | -45 | -7 | -53 | 59 | -79 | -65 | -94 |
| EPS reported | $ | -1.17 | -1.55 | |||||
| Operating cashflow per share | $ | -1.07 | -1.07 | |||||
| Capex per share | $ | 0.01 | 0.01 | |||||
| FCF per share | $ | -1.08 | -1.08 | |||||
| Free cash flow | $m | -60 | -84 | |||||
| Net debt | $m | -69 | -56 | |||||
| Book value equity | $m | 93 | 49 | |||||
| Book value per share | $ | 1.68 | 0.81 | |||||
| Number of shares | m | 55.76 | 60.72 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.49 | 1.32 | |||||
| P/S LTM | x | 1.52 | 2.17 | |||||
| P/FCF LTM | x | -0.76 | -0.78 | |||||
| EV/EBITDA LTM | x | -0.82 | -0.10 | |||||
| EV/Sales LTM | x | 1.70 | 0.29 | |||||
| Earnings Yield LTM | % | -142.82% | -109.45% | |||||
| FCF Yield | % | -131.33% | -128.96% | |||||
| Quality | ||||||||
| ROE | % | -69.92% | -61.52% | |||||
| ROIC | % | -41.40% | -41.40% | |||||
| Operating margin | % | -206.23% | -206.23% | |||||
| Gross margin | % | 100.00% | 100.00% | |||||
| FCF/Sales | % | -200.16% | -200.16% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +1016.5% | -1.79% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -1.07 | -8.85 | |||||
| Net Debt/EBITDA | x | -0.08 | -0.08 | |||||
| EBIT/Net interest | x | -36.03 | -36.03 | |||||
| Net debt/market cap | % | -150.44% | -86.44% | |||||
| Net debt/Equity | x | -0.74 | -1.14 | |||||
| Gross debt/equity | x | 0.60 | 0.19 | |||||
Company overview
Surface Oncology, Inc. is a clinical-stage biotechnology firm focused on discovering and developing innovative immuno-oncology treatments for cancer patients in the United States. Its pipeline features a range of antibody-based therapeutics, including NZV930, a fully human IgG4 monoclonal antibody designed to modulate extracellular adenosine production, and SRF617, another human IgG4 monoclonal antibody that aims to block CD39's enzymatic activity, thereby influencing adenosine levels and ATP degradation. Other key candidates include SRF388, which targets interleukin 27; GSK4381562, an antibody aimed at CD112R, an inhibitory protein found on natural killer and T cells; and SRF114, which targets the chemokine receptor CCR8. The company also maintains strategic partnerships, holding a licensing agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited for the development, manufacturing, and commercialization of SRF813-targeting antibodies. Furthermore, it has a separate licensing deal with Vaccinex, Inc. concerning the development, production, and commercialization of antibodies targeting SRF114. Established in 2014, Surface Oncology, Inc. operates from its headquarters in Cambridge, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Surface Oncology, Inc. (SURF)
Surface Oncology, Inc. is a clinical-stage biotechnology firm focused on discovering and developing innovative immuno-oncology treatments for cancer patients in the United States. Its pipeline features a range of antibody-based therapeutics, including NZV930, a fully human IgG4 monoclonal antibody designed to modulate extracellular adenosine production, and SRF617, another human IgG4 monoclonal antibody that aims to block CD39's enzymatic activity, thereby influencing adenosine levels and ATP degradation. Other key candidates include SRF388, which targets interleukin 27; GSK4381562, an antibody aimed at CD112R, an inhibitory protein found on natural killer and T cells; and SRF114, which targets the chemokine receptor CCR8. The company also maintains strategic partnerships, holding a licensing agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited for the development, manufacturing, and commercialization of SRF813-targeting antibodies. Furthermore, it has a separate licensing deal with Vaccinex, Inc. concerning the development, production, and commercialization of antibodies targeting SRF114. Established in 2014, Surface Oncology, Inc. operates from its headquarters in Cambridge, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free